Lisata Therapeutics Inc. (NASDAQ:LSTA) saw a downside of -0.98% to $3.02 after subtracting -$0.03 on Tuesday. The 5-day average trading volume is 134,839 shares of the company’s common stock. It has gained $3.62 in the past week and touched a new high 2 times within the past 5 days. An average of 42,805 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 25,654.
LSTA’s 1-month performance is -16.80% or -$0.46 on its low of $2.75 reached on 08/08/23. The company’s shares have touched a 52-week low of $2.36 and high of $9.75, with the stock’s rally to the 52-week high happening on 06/14/23. YTD, LSTA has achieved 19.37% or $0.64 and has reached a new high 18 times. However, the current price is down -69.03% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
LSTA stock has a beta of 1.20. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 0.40.
Lisata Therapeutics Inc.’s quick ratio for the period ended March 30 was 12.40, with the current ratio over the same period at 12.40.
Earnings Surprise
For the quarterly period ending March 30 this year, Lisata Therapeutics Inc.’s cash and short-term investments amounted to $37.07 million against total debt of $0.42 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -13.36% to -$5.99 million, while revenue of -$37.38 million was -524.04% off the previous quarter. Analysts expected LSTA to announce -$0.81 per share in earnings in its latest quarter, but it posted -$0.77, representing a 4.90% surprise. EBITDA for the quarter stood at more than -$6.96 million. LSTA stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 5.62 million, with total debt at $0.42 million. Shareholders hold equity totaling $7.97 million.
Let’s look briefly at Lisata Therapeutics Inc. (LSTA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 40.33% to suggest the stock is trending Neutral, with historical volatility in this time period at 52.82%.
The stock’s 5-day moving average is $3.16, reflecting a -0.94% or -$0.03 change from its current price. LSTA is currently trading -13.15% above its 20-day SMA, -4.52% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -18.72% and SMA200 by-23.24%.
Stochastic %K and %D was 23.11% and 19.53% and the average true range (ATR) pointed at 0.23. The RSI (14) points at 38.53%, while the 14-day stochastic is at 44.21% with the period’s ATR at 0.21. The stock’s 9-day MACD Oscillator is pointing at -0.02 and -0.11 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for LSTA stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate LSTA as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
